Related Experiment Video
Updated: May 15, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Lamotrigine augmentation in premenstrual dysphoric disorder: a case report
Gianna Sepede1, Giovanni Martinotti, Francesco Gambi
1Department of Neuroscience and Imaging, Chair of Psychiatry, G d'Annunzio University of Chieti, Chieti, Italy. g.sepede@unich.it
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome, characterized by depressive, anxious, and somatic symptoms, associated to a significant reduction in social functioning and quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and oral contraceptives show a substantial effectiveness in PMDD, a wide percentage of women affected by PMDD do not respond to those first-line treatments. We present the case of a 42-year-old woman, affected by a disabling form of PMDD, who partially responded to an SSRI treatment and significantly improved after an add-on therapy with lamotrigine. We therefore suggest that lamotrigine may be an efficacious and safe augmentation strategy in severe PMDD cases showing unsatisfactory or partial response to SSRI treatments.
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome, characterized by depressive, anxious, and somatic symptoms, associated to a significant reduction in social functioning and quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and oral contraceptives show a substantial effectiveness in PMDD, a wide percentage of women affected by PMDD do not respond to those first-line treatments. We present the case of a 42-year-old woman, affected by a disabling form of PMDD, who partially responded to an SSRI treatment and significantly improved after an add-on therapy with lamotrigine. We therefore suggest that lamotrigine may be an efficacious and safe augmentation strategy in severe PMDD cases showing unsatisfactory or partial response to SSRI treatments.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Therapeutic Drug Monitoring: Affecting Factors
Antidepressant Drugs: Overview
Bipolar Disorder